Lone Star Agrees to Acquire Central London Office Building February 26, 2026 Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has reached an agreement to acquire 90 Whitfield Street in London, UK from Derwent London. The property, located in central London’s West End sub-market of Fitzrovia, is comprised of 107,000 total square-feet with 99,000 square-feet dedicated to [...]
CoStar Data Show Sharp London Office Yield Compression in 2025 February 26, 2026 Rising investor demand drove London office yields to their lowest level since 2023, according to data from CoStar, a global leading provider of online real estate marketplaces, information and analytics in the property markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226000995/en/ Based on a three-period trailing average, the transaction-based office yield [...]
FTSE 100 Live: WPP sinks; LSEG, Rolls-Royce bumper buybacks February 26, 2026 Good morning and welcome back to the City AM liveblog. After a few days of tariff-induced risk aversion, the FTSE 100 was back on blistering form on Wednesday, finishing the day’s trading session with a new record. London’s blue-chip index soared over one per cent to seal yet another record close at 10,806.41p. This was [...]
Courtrooms in the cloud: How Opus 2 quietly changed the game February 26, 2026 AI is making its mark on the legal profession, an industry renowned for its cautious approach to change. Yet, behind the scenes, innovative technologies have been quietly transforming courtrooms for years. If you ever sat behind the row of barristers and the lawyers that instructed them in a courtroom at the High Court, you may [...]
On this day: The collapse of Barings Bank February 26, 2026 On 26 February 1995, 31 years ago today, Baring Bank, one of the City’s most venerable institutions, was declared insolvent after a massive fraud by one of its employees, Nick Leeson, recalls Eliot Wilson In the 1990s, following the wake of Big Bang and the influx of brash but wealthy, “Greed is good, greed is [...]
It’s a sad story from brewery to pub February 26, 2026 It was a balmy 17 degrees in the Square Mile yesterday, drawing crowds out for a lunchtime pint in the sun. But in other parts of the country the hospitality sector is still in the grip of winter. Bad news came thick and fast from my native Cornwall yesterday, starting with confirmation that Sharp’s Brewery [...]
Employment law changes could mean huge payouts for under-performing private equity execs February 26, 2026 Private equity often hires on a “perform, or else” basis, with senior executives are left exposed to deliver positive results (and fast). But changes to employment will make it harder – and more expensive – to sack anyone with more than six months’ service, writes Jade Gooding The challenges facing the UK economy continue to [...]
Buy more small caps, says Panmure Liberum. But which ones? February 26, 2026 Now is the time to get back into British small caps, according to the boffins at Panmure Liberum. Headline valuations, on a P/E ratio basis, don’t seem much different in the small caps compared to their big-cap counterparts. But Panmure says that when you adjust for differences in sector composition, you get an average discount [...]
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing February 25, 2026 VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an enhanced resistance profile versus bictegravir VH499 demonstrates good tolerability, supporting twice-yearly dosing intervals
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen February 25, 2026 94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir These phase IIb results reinforce lotivibart’s ultra long-acting potential, with the trial progressing to evaluate a twice-yearly intravenous dosing interval